GSA Press Release

Axolotl Biologix Products Approved and Added to the General Services Administration’s Federal Supply Schedule

Award Allows the VA, Indian Health Services and Other Federal Agencies to Order and

Prescribe Axolotl Biologix Products

Phoenix, AZ (January 14, 2019) - Axolotl Biologix, a biotechnology leader in regenerative

medicine, is proud to announce that the General Services Administration (GSA) has added

Axolotl Biologix’s products to the Federal Supply Schedule (FSS).

The GSA award will allow physicians and staff of federal agencies, such as the Veterans

Administration and Indian Health Services, to order Axolotl Biologix products when seeking

remedies to promote repair or regeneration of damaged tissues. Products now available through

the FSS to address these issues include Axolotl Biologix’s lines of regenerative fluid and

membrane allografts.

“We are thrilled that Axolotl Biologix products have been added to the GSA’s Federal Supply

Schedule which allows government agencies to order our products as they develop treatment

plans for their patients,” said Phillip Larson, President of Axolotl Biologix. “Approval and

inclusion in the FSS will provide patients and their physicians additional care options.”

Axolotl Biologix currently has three products available on the GSA’s FSS and have begun the

process to add additional products in the months and years ahead. Its liquid allograft products

come in both cryopreserved and ambient temperatures giving medical facilities more flexibility

to have products on-hand as needed, while Axolotl Biologix’s membrane allograft products

assist with wound care.

GMP- Government Marketing & Procurement, LLC assisted Axolotl Biologix in the process to be added to the GSA’s FSS.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through

research, technology and clinical application. Axolotl Biologix is expanding the human body’s

ability to regenerate by developing and manufacturing regenerative human cell and tissue

medical technologies that are disrupting traditional, more invasive, painful and expensive

treatment protocols. For more information, visit


Media Contact:

Josh Weiss

10 to 1 Public Relations


Laura Slawny

10 to 1 Public Relations